Skip to main content

Table 1 Baseline characteristics of patients with hyperglycaemic crisis in the training set and test set

From: Mortality prediction in patients with hyperglycaemic crisis using explainable machine learning: a prospective, multicentre study based on tertiary hospitals

Variables

Training set

(n = 257)

Test set

(n = 80)

Demographic data

  

Age, years

56.0 (40.3, 70.0)

51.0 (35.0, 61.0)

Sex, %

  

 Male

152 (59.1)

46 (57.5)

 Female

105 (40.9)

34 (42.5)

Body mass index, kg/m2

22.7 (20.1, 25.0)

22.8 (20.6, 26.1)

Diabetes type, %

  

 Type 1

37 (14.4)

14 (17.5)

 Type 2

220 (85.6)

66 (82.5)

Clinical and laboratory data

  

Blood glucose, mmol/L

33.1 (21.6, 33.6)

27.3 (20.6, 40.2)

β-hydroxybutyrate, mmol/L

3.80 (1.50, 6.00)

5.60 (3.40, 6.85)

Hemoglobin A1c, %

11.6 (10.0, 13.5)

12.8 (11.0, 14.3)

Triglyceride, mmol/L

1.95 (1.33, 3.02)

1.62 (1.10, 3.30)

Total cholesterol, mmol/L

4.80 (3.80, 6.27)

4.50 (3.53, 5.51)

LDL-C, mmol/L

2.57 (1.78, 3.37)

2.53 (1.66, 3.19)

Serum creatinine, umol/L

82.0 (58.0, 144.1)

79.5 (57.6, 120.8)

Blood urea nitrogen, mmol/L

7.86 (5.40, 15.40)

7.81 (5.15, 16.10)

Cystatin C, mg/L

1.16 (0.71, 2.20)

0.74 (0.61, 1.21)

Creatine kinase, U/L

95.0 (58.0, 208.0)

83.0 (46.6, 123.6)

Cardiac troponin I, μg/L

0.01 (0.00, 0.04)

0.01 (0.01, 0.03)

CKMB, U/L

14.0 (8.3, 20.8)

16.6 (11.2, 25.6)

Alanine aminotransferase, IU/L

19.0 (13.0, 30.0)

18.0 (12.1, 29.6)

Aspartate aminotransferase, IU/L

18.0 (13.0, 28.3)

17.8 (13.2, 26.8)

C-reactive protein, mmol/L

9.10 (4.20, 55.66)

4.56 (0.66, 14.30)

Procalcitonin, ng/ml

0.47 (0.08, 2.25)

0.15 (0.10, 2.20)

White blood cells, × 109/L

10.6 (6.8, 14.8)

7.24 (10.89, 15.71)

Percentage of neutrophils, %

84.0 (74.0, 90.0)

86.5 (78.6, 91.4)

Lymphocyte, × 109/L

1.06 (0.62, 1.59)

1.23 (0.76, 1.91)

Platelet, × 109/L

196.0 (153.0, 259.0)

214.5 (169.8, 284.3)

Serum sodium, mmol/L

142.3 (135.2, 149.5)

136.5 (133.0, 142.0)

Serum potassium, mmol/L

4.03 (3.66, 4.66)

4.15 (3.64, 4.92)

Serum chloride, mmol/L

100.1 (95.8, 106.0)

104.5 (97.8, 112.0)

PH

7.31 (7.22, 7.38)

7.30 (7.19, 7.36)

Base excess, mmol/L

− 7.30 (− 15.70, − 2.70)

− 9.90 (− 17.83, − 6.55)

HCO3−, mmol/L

14.9 (9.2, 18.0)

14.5 (8.3, 16.9)

Effective serum osmolality, mOsm/kg

314.0 (293.0, 335.5)

299.0 (289.0, 327.2)

Medical history

  

Infection, n (%)

147 (57.2)

30 (37.5)

Septic shock, n (%)

7 (2.7)

0 (0.0)

Hypertension, n (%)

66 (25.7)

16 (20.0)

Coronary heart disease, n (%)

29 (11.3)

8 (10.0)

Heart failure, n (%)

12 (4.7)

0 (0.0)

Cerebral infarction, n (%)

44 (17.1)

4 (5.0)

Dementia, n (%)

5 (1.9)

0 (0.0)

Diabetic nephropathy, n (%)

43 (16.7)

11 (13.8)

Acute kidney injury, n (%)

8 (3.1)

6 (7.5)

Tumor, n (%)

3 (1.2)

3 (3.8)

Death, n (%)

31 (12.1)

15 (18.8)

  1. LDL-C low-density lipoprotein cholesterol, CKMB creatinine kinases MB isoenzyme, PH hydrogen ion concentration index, HCO3− serum bicarbonate ion concentration
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us